Benjamin Lund

Perceptive Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Joseph “Joe” Edelman in 1999. provides investment advice to private funds, separate accounts, and co-investment vehicles. Investors in the client accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, and high-net-worth individuals.

RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom.

Freenome Holdings, Inc. engages in the development of multiomics platform for early cancer detection. It develops simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. The company was founded by Charles Roberts, Riley Ennis, and Gabriel Otte and is headquartered in South San Francisco, CA.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York.

Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA.

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

KBI Services, Inc. provides women healthcare and fertility services. It offers in vitro fertilization services. The company was founded by Joanne Schneider and Gina Bartasi in April 2018 and is headquartered in New York, NY.

Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL.

RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.

DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA.